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Abstract
Introduction Overexpression of the HER2/neu gene in breast
cancer is associated with an increased incidence of metastatic
disease and with a poor prognosis. Although passive
immunotherapy with the humanized monoclonal antibody
trastuzumab (Herceptin) has shown some effect, a vaccine
capable of inducing T-cell and humoral immunity could be more
effective.
Methods Virus-like replicon particles (VRP) of Venezuelan
equine encephalitis virus containing the gene for HER2/neu
(VRP-neu) were tested by an active immunotherapeutic
approach in tumor prevention models and in a metastasis
prevention model.
Results VRP-neu prevented or significantly inhibited the growth
of HER2/neu-expressing murine breast cancer cells injected
either into mammary tissue or intravenously. Vaccination with
VRP-neu completely prevented tumor formation in and death of
MMTV-c-neu transgenic mice, and resulted in high levels of neu-
specific CD8+ T lymphocytes and serum IgG.
Conclusion On the basis of these findings, clinical testing of
this vaccine in patients with HER2/neu+  breast cancer is
warranted.
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Introduction
The management of breast cancer currently relies on sur-
gery, chemotherapy and radiotherapy. Despite recent
advances in clinical management of breast cancer once
metastasis has occurred, the probability of a complete cure
is greatly reduced. Of the women who have no detectable
lymph node metastases at the time of diagnosis, up to one-
third later develop metastases [1]. In patients with meta-
static disease that does not respond to radiotherapy or
chemotherapy, immunotherapy may offer an additional form
of cancer control [2-4]. Clinical trials of trastuzumab, a
monoclonal antibody specific for HER2/neu, have demon-
strated the utility of an immunologic approach for breast
cancers that overexpress this gene [5-7]. A drawback to
'passive' immunotherapy using monoclonal antibodies is
that the effect is short-lived. An alternative approach is
active vaccination that could induce neu-specific cytotoxic
T cells with the ability to control the growth of the primary
tumor and metastases. However, unlike passive immuno-
therapy whose effectiveness quickly wanes, effector and
memory T cells induced by vaccination may remain present
and be able to respond to any metastatic cells expressing
HER2/neu that arise after treatment.
HER2/neu is an excellent target for gene vaccines, and
several preclinical studies have shown the effectiveness of
plasmid vaccines encoding neu in murine models [8-16].
Using a plasmid markedly different from those previously
described [8-16], we created an effective gene vaccine
against HER2/neu [17]. The previously described ELVIS
plasmid vaccine construct for HER2/neu  contained the
cDNA of a replicon RNA from the Alphavirus Sindbis
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[18,19]. The replicon RNA contained the replication/tran-
scription genes of the parent virus, but the structural pro-
tein genes were replaced by the gene for rat neu. From this
plasmid construct, the replicon RNA is synthesized in the
nucleus of the host cell and is transported to the cytoplasm
for replication and transcription. The neu gene product is
produced at high levels in the cytosol. Since the structural
protein genes from the parent virus are not encoded by the
replicon, progeny infectious Sindbis virions are not gener-
ated [20-22].
Alternatives to Alphavirus replicon plasmid vaccines
[17,19,23-25] are Alphavirus-based virus-like replicon par-
ticles (VRP). As already mentioned, the replicon RNA does
not contain the structural genes from the parent virus. It is
therefore a single-cycle, propagation-defective RNA and
replicates only within the cell into which it is introduced. To
generate VRP from an attenuated strain of the Alphavirus
Venezuelan equine encephalitis virus (VEE), the replicon
RNA is packaged into particles by co-transfecting the rep-
licon RNA and two separate helper RNAs, which together
encode the full complement of VEE structural proteins [26].
Although the VRP can infect target cells in culture or in
vivo, and can express the foreign gene to a very high level,
the VRP are defective since they lack critical portions of the
VEE genome – they lack the VEE structural protein genes
necessary to produce infectious virus particles capable of
spreading to other cells [21,27].
Several reports have demonstrated that VRP are extremely
effective vaccine vectors [28-39]. The VEE VRP vaccine
vectors are particularly attractive because the VEE enve-
lope glycoproteins target the VRP to cells of lymphoid tis-
sue [40], because they can be administered multiple times
[39], because they induce both cellular and humoral
immune responses, and because pre-existing immunity to
VEE in humans should not be problematic since the inci-
dence of VEE infection is low.
In the current study, we sought to determine whether vac-
cination with VEE-derived VRP containing the gene for
HER2/neu would inhibit tumor growth in prevention models
in which HER2/neu-expressing tumor cells had been
injected either into a mammary fat pad or intravenously. We
also sought to determine whether vaccination could pre-
vent spontaneous tumorigenesis in HER2/neu transgenic
mice. VRP-neu vaccination induced antigen-specific CD8+
T-cell and IgG responses that corresponded with the lack
of tumor growth in both tumor models. In light of the clinical
benefit of trastuzumab, a safe and effective vaccine that
can induce cellular and humoral immunity, VRP-neu war-
rants clinical evaluation.
Materials and methods
Tumor cell line and reagents
The A2L2 cell line that expresses high levels of rat HER2/
neu has been previously described in detail [17]. The A2L2
cell line has consistently expressed high levels of HER2/
neu for more than 5 years and consistently induces tumors
in Balb/c mice when injected into a mammary fat pad or
intravenously. The A2L2 cell line was maintained in Eagle's
MEM containing 5% FCS, sodium pyruvate, nonessential
amino acids, L-glutamine, and vitamins (GIBCO, Carlsbad,
CA, USA). The monolayer cultures were subdivided at
approximately 75% confluence by treatment for 1–3 min
with 0.25% trypsin and 0.02% EDTA at 37°C.
Virus-like replicon particles
The pSV2-neu plasmid containing the gene for rat HER2/
neu was provided by Dr Mien-Chie Hung (The University of
Texas MD Anderson Cancer Center, Houston, TX, USA).
VEE VRP were constructed at AlphaVax, Inc. (Research Tri-
angle Park, NC, USA) according to the published proce-
dure [26]. Control VRP containing the gene for A/PR/8/34
influenza hemagglutinin (HA) were also prepared following
the same procedure. VRP preparations were screened in a
sensitive in vitro Vero cell cytopathic effect assay for the
detection of replication competent virus. Prior to their use
in these studies, the preparations were shown to be devoid
of detectable replication competent virus.
Flow cytometry
A2L2 cells were incubated for 1 hour at 37°C with either
immune serum or control serum diluted in PBS. FITC-
labeled goat anti-mouse IgG diluted 1:1000 in PBS was
added to the cells and incubation was continued for 1 hour
at 37°C. The cells were washed three times in PBS and
were analyzed by flow cytometry using an EPICS Profile
Analyzer (Beckman Coulter, Inc., Fullerton, CA, USA).
Mice
Female Balb/c mice, aged 6–8 weeks, were obtained from
the Frederick Cancer Research Facility (Frederick, MD,
USA). Mice were allowed to acclimate for at least 1 week
before use. Six-week-old MMTV-c-neu  transgenic mice
were obtained from Charles River Laboratories Inc. (Wilm-
ington, MA, USA). This strain of mice is called the 'Onco-
mouse' by Charles River Laboratories due to the
spontaneous generation of breast cancer. These mice are
of the FVB/N strain, and the transgene is the 'activated' rat
c-neu oncogene preceded by the MMTV promoter [41].
Vaccination with VRP
Mice were vaccinated subcutaneously in the hind foot pad
with VRP suspended in 50 µl normal saline. Repeat vacci-
nations, when administered, were performed using alter-
nate hind feet. Tail vein blood was removed and tumor
challenge performed 2 weeks after the final vaccination.Available online http://breast-cancer-research.com/content/7/1/R145
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Serum was separated from the blood by centrifugation
after overnight storage at 4°C.
Mammary fat pad tumor prevention model
A2L2 cells were harvested from subconfluent cultures with
trypsin and EDTA as described earlier. The cells were
washed once in serum-containing culture medium and
were washed once in PBS. Mice were anesthetized by
inhalation of isoflurane using a special apparatus devel-
oped by the veterinarians at MD Anderson Cancer Center.
The fur was shaved over the lateral thorax, and a 5-mm-long
incision was made to reveal mammary fat pad 2 as previ-
ously described [42]. A 0.1-ml sample containing 2.5 × 104
A2L2 cells in normal saline was injected into the fat pad.
The incision was closed with a wound clip. Wound clips
that had not already fallen off were removed after 7 days.
The mice were then observed daily and their tumors meas-
ured in perpendicular directions with a pair of calipers.
Mice with tumors 10 mm in the greatest dimension were
killed according to our approved Institutional Animal Care
and Use protocol. At the termination of the experiment, all
mice were killed by CO2 inhalation and all tumors were
excised and weighed.
Experimental metastasis prevention model
A 0.1-ml sample containing 2.5 × 104 A2L2 cells in normal
saline was injected into the tail vein of each immunized
mouse. The mice were killed 30 days later, and the surface
lung metastases in each animal were counted.
Tetramer analysis of immune spleen cells
A K(d) tetramer containing the peptide sequence PYVSR-
LLGI [43] was prepared by the National Institutes of Health
Tetramer Facility at Emory University (Atlanta, GA, USA).
The incorporated peptide was synthesized at the peptide
synthesis facility of MD Anderson Cancer Center. We
received a K(d) tetramer specific for A/PR/8/34 influenza
HA containing the peptide IYSTVASSL from Linda Sher-
man at the Scripps Research Institute (La Jolla, CA, USA)
[44]. A single-cell suspension of the spleen from a naïve
mouse was prepared in R10S medium (RPMI 1640, 10%
HI-FCS [Summit Biotechnology, Fort Collins, CO, USA],
1% nonessential amino acids, 100 mM MEM sodium pyru-
vate, 2 mM L-glutamine, 100 U/ml penicillin, 1 ml strepto-
mycin, and 50 mM 2-mercaptoethanol) by gently swirling
the spleen between frosted glass slides.
Debris was removed from the cell suspension by filtration
through nylon mesh into a 10-ml centrifuge tube. The cell
suspension was centrifuged for 10 min at 700 × g and the
pellet resuspended in 5 ml ACK solution (0.15 M NH4Cl,
1.0 mM KHCO3, 0.01 mM NaEDTA, pH adjusted with 1 N
HCl to 7.2–7.4) before being gently rocked for 5 min to lyse
red blood cells. An additional 5 ml R10S medium was
added to the cell suspension, and the cells were washed
once with R10S medium. The naïve spleen cells were cul-
tured with either PYVSRLLGI or IYSTVASSL (70 ng/ml) on
a rocker for 2 hours at 37°C and were γ-irradiated with 20
Gray.
The mice were vaccinated three times with a 2-week inter-
val with 106 infectious units (IU) VRP-neu or 106 IU VRP-
HA, and the immune spleens were harvested 3 weeks after
the final vaccination. The immune spleens were prepared to
produce a single cell suspension in R10S medium and
were co-cultured with the peptide-pulsed stimulator cells at
a ratio of one stimulator to eight responders. The cell mix-
ture was cultured for 7 days at 37°C, washed, and was
resuspended in FACS buffer (PBS with 1% BSA) at a con-
centration of 5 × 107 cells/ml. Twenty microliters of the cell
mixtures were added to 20 µl PE-conjugated Her2/neu-
specific or HA-specific tetramers to make the final dilutions
of the tetramers 1:50, 1:100, and 1:200. One microliter of
PerCP-conjugated anti-mouseCD3e (PharMingen, San
Diego, CA, USA) and FITC-conjugated anti-mouse CD8a
(Caltag, Burlingame, CA, USA) was added to the mixture
and incubated for 1 hour at 4°C in the dark. The cells were
then suspended in 150 µl FACS buffer and transferred to
a polystyrene round-bottomed tube. The cells were washed
twice with FACS buffer and suspended in 200 µl of 1%
paraformaldehyde in PBS.
List mode data were acquired with a FACScan (BD Bio-
sciences, San Jose, CA, USA). Dead cells and monocytes
were excluded from the analysis by forward scatter and
side scatter gating. A total of 10,000–30,000 events were
typically acquired, and compensation was optimized using
unstained cells, cells stained with only PerCP-conjugated
anti-mouse CD3e, cells stained with only FITC-conjugated
anti-mouseCD8a and cells stained with only PE-conju-
gated anti-mouse CD4. The CD3+ cells were gated from
the total population of live cells, and the CD8+ cells were
gated from the CD3+ cells. From the CD3+ cells and the
CD8 double-positive cells, the percentages of PE-tetramer-
positive cells were calculated. Isotype controls for the anti-
CD3e and anti-CD8a were subtracted from the acquired
data. List mode files were analyzed using CELLQUEST
software (BD Biosciences, San Jose, CA, USA).
Intracellular interferon-γ analysis of immune spleen cells
The procedure for this technique was obtained from
PharMingen, whose reagents were used whenever possible.
Spleens from VRP-neu-immunized and VRP-HA-immunized
mice were prepared as already described for tetramer analy-
sis. The spleen cells were stimulated with PYVSRLLGI at a
concentration of 70 ng/ml at 37°C in R10S medium for 5
days as described. On the sixth day, the cells were sus-
pended at 2 × 106/ml in R10S medium containing 10 ng/ml
phorbol-12-myristate acetate (Sigma-Aldrich, St Louis, MO,
USA) and 250 ng/ml ionomycin (Sigma-Aldrich). Brefeldin (1Breast Cancer Research    Vol 7 No 1    Wang et al.
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µl/ml; Sigma-Aldrich) was added at the same time to block
cytokine secretion. The cells were washed after 5 hours and
resuspended at 107 cells/ml in staining buffer (Dulbecco's
PBS without Mg2+or Ca2+, 1% heat-inactivated FCS, w/v
0.09% sodium azide; pH adjusted to 7.4–7.6). The cells
were then incubated for 15 min with purified 2.4 G2 anti-
body 10 µg/ml (PharMingen) to block nonspecific staining
by fluorochrome-conjugated antibodies via Fc receptors.
The cells were washed twice with staining buffer, and 106
cells were stained with 1 µg FITC-labeled anti-mouse CD8a
and PerCP-labeled anti-mouse CD3e (PharMingen) in 50 µl
staining buffer at 4°C for 30 min. The cells were again
washed twice with staining buffer, followed by fixation and
permeabilization with Perm/Wash (Cytofix/Cytoperm Kits;
PharMingen) for 20 min at 4°C. The cells were washed twice
and resuspended in 50 µl of the same solution. PE-conju-
gated anti-interferon (IFN)-γ monoclonal antibody (0.5 µg/
106 cells; PharMingen) was added and the suspension was
incubated for 30 min at 4°C. The cells were then washed
twice with Perm/Wash solution and resuspended in staining
buffer.
The FACScan was used to analyze the percentage of intra-
cellular IFN-γ-containing cells among the CD3+ and CD8+
cells. Isotype controls for anti-CD3a, anti-CD8e, and anti-
IFN-γ (PharMingen) were subtracted from the acquired data.
ELISPOT analysis of IFN-γ production by immune spleen 
cells
The procedure for the ELISPOT technique was obtained
from PharMingen, whose reagents were used whenever
possible. The wells of an ELISPOT plate (CTL Immunospot
plate; Cellular Technology Ltd, Cleveland, OH, USA) were
coated overnight at 4°C with 100 µl anti-mouse IFN-γ (2
µg/ml; PharMingen) diluted at 1:200 in coating buffer
(PBS, pH 7.2). The coated wells were washed with block-
ing solution (R10S medium), fresh blocking solution was
added to each well, and then the plate was incubated for 2
hours at room temperature. The blocking solution was then
discarded and 100 µl A2L2 cells (2 × 105-1 × 106) was
added to each well of the ELISPOT plate.
Immune spleens were dissected from vaccinated mice and
were prepared as already described for tetramer analysis.
Increasing numbers of spleen cells (5 × 106 - 2 × 107) in 100
µl R10S medium were added to the wells, and the plate was
incubated for 24 hours at 37°C in a 5% CO2 atmosphere at
99% humidity. Wells containing only spleen cells served as
negative controls, and spleen cells from VRP-neu-vacci-
nated mice cultured overnight with 5 µg/ml concanavalin A
(Sigma-Aldrich) served as a positive control. The cell sus-
pension was aspirated, and the wells were washed twice
with deionized water and were then soaked with deionized
water for 5 min. The wells were washed three times with
wash buffer I (PBS containing 0.05% Tween-20).
The detection antibody, biotinylated anti-mouse IFN-γ
(PharMingen), was diluted to 2 µg/ml in dilution buffer (PBS
containing 10% FBS), and 100 µl was added to each well.
The plate was incubated at room temperature for 2 hours,
and the wells were washed three times with buffer I. Avidin–
horseradish peroxidase reagent (PharMingen) was diluted to
1:100 in dilution buffer, and 100 µl was added to each well,
which was then incubated at room temperature for 1 hour.
The wells were washed four times with wash buffer I and
twice with wash buffer II (PBS). A stock solution containing
100 mg 3-amino-9-ethyl-carbazole (Sigma) dissolved in 10
ml N, N-dimethylformamide (Sigma-Aldrich) was prepared.
The final substrate solution was made by adding 333 µl 3-
amino-9-ethyl-carbazole stock solution to 10 ml of 0.1 M
sodium acetate (pH 5.0), followed by filtering through a
0.45-µm filter. Five microliters of 30% H2O2 was added to
the substrate solution immediately before use.
One hundred microliters of the final substrate solution was
added to each well, and the plate was incubated in the dark
for 5–60 min at room temperature. The reaction was
stopped by washing the wells with deionized water. The
plate was air-dried overnight at room temperature in the
dark and sent to ZellNet Consulting, Inc. http://www.zell
net.com, where the spots were enumerated automatically
using an ImmunoSpot Series I analyzer (BD Biosciences).
If overlapping spots (confluence) were present in the wells,
the number of spots in a nonconfluent area of that well was
determined. To estimate the total number of spots in each
well with confluence, the following equation was used: total
spot number = spot count + 2 × (spot count × % conflu-
ence / [100% - % confluence]).
Statistical analysis
Student's t test was performed using Prism 4.0 Graphpad
Software (San Diego, CA, USA). Statistical analysis, power
analysis and the sample size per group were evaluated and
found to be statistically acceptable by Dr Lyle Broemling
(Associated Professor of Biostatistics, The University of
Texas MD Anderson Cancer Center).
Results
Induction of antigen-specific IgG by vaccination with 
VRP-neu
Groups of Balb/c mice (n = 5 per group) were vaccinated
once subcutaneously in one hind leg footpad with either
106 IU VRP-neu or 106 IU VRP-HA suspended in PBS. The
HER2/neu-specific humoral response of serum pooled
from mice in each group was measured 14 days later by
flow cytometry using A2L2 cells. Compared with the mice
vaccinated with VRP-HA, the mice vaccinated with VRP-
neu had a strong IgG response (Fig. 1). Pre-immune sera
for both groups were nonreactive with A2L2 cells, and
immune sera from both vaccinated groups were nonreac-Available online http://breast-cancer-research.com/content/7/1/R145
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tive with 66.3 cells, the parental cell line from which A2L2
was derived by transfection with neu (data not shown).
Protection from tumor challenge in a mammary fat pad 
prevention model following vaccination with VRP-neu
Groups of mice (n = 7 per group) were vaccinated subcu-
taneously with 105 IU or 106 IU VRP-neu or with 106 IU
VRP-HA three times at 14-day intervals. Two weeks after
the final vaccination, the mice were challenged with 2.5 ×
104 A2L2 cells injected into a mammary fat pad. Five weeks
after tumor challenge, the largest tumor dimension was
measured and the mice were killed. If a tumor was present,
its mass was determined. All of the mice vaccinated with
VRP-HA had a measurable tumor, whereas only one mouse
in each group vaccinated with 106 IU VRP-neu or 105 IU
VRP-neu had a measurable tumor (Fig. 2a,2b). These find-
ings clearly demonstrate that vaccination three times with
either 105 IU or 106 IU VRP-neu protected mice from chal-
lenge with A2L2 cells. VRP-HA failed to provide protection
for any of the mice, and therefore the protective effect was
specific for the vaccine containing the gene for HER2/neu.
Determination of the minimal effective vaccine dose in 
two tumor prevention models
Because vaccination three times with 105 IU VRP-neu pre-
vented tumor growth in a mammary fat pad, we next deter-
mined the minimum number of VRP-neu particles and the
minimum number of vaccinations necessary to significantly
inhibit tumor growth. In the mammary fat pad prevention
model, vaccination twice with 105 IU VRP-neu or vaccination
three times with 104 IU VRP-neu  completely prevented
tumor growth in many mice and significantly reduced the
tumor mass in the entire group compared with the tumor
mass of the mice vaccinated three times with VRP-HA (Fig.
3a). Identical results were obtained in the experimental lung
metastasis prevention model, in which mice were injected
with A2L2 cells intravenously in the tail vein after vaccination
(Fig. 3b). These results demonstrate that, in both tumor mod-
els, vaccination three times with 104 IU VRP-neu or twice
with 105 IU VRP-neu significantly reduced the tumor mass
and lung metastasis. In addition, several mice in each vacci-
nated group were tumor free in mammary tissue or lungs.
Vaccination of MMTV-c-neu transgenic mice
MMTV-c-neu transgenic mice contain the activated rat neu
gene under the control of the MMTV promoter and sponta-
neously develop neu+ breast tumors within 110–120 days
[45]. Without intervention, all of the mice die of breast
cancer. We vaccinated groups of mice (n = 10 per group)
three times at 14-day intervals with 106 IU VRP-neu or 106
IU VRP-HA and determined the effect on survival. Eight of
the 10 mice vaccinated with VRP-HA were killed by 140
days owing to moribundity, and the remaining two mice
were killed on day 195 (Fig. 4). None of the mice vacci-
nated with VRP-neu  showed any sign of illness at 240
days, and breast tumors were not evident on palpation. The
mice in the VRP-neu-vaccinated group were killed at this
time, and gross pathologic examination of the breasts fol-
Figure 1
Flow cytometric analysis of A2L2 cells with serum from mice vaccinated with virus-like replicon particles (VRP)-neu or VRP-hemagglutinin (HA) Flow cytometric analysis of A2L2 cells with serum from mice vaccinated with virus-like replicon particles (VRP)-neu or VRP-hemagglutinin (HA). 
Serum was collected 2 weeks after a single vaccination of Balb/c mice with 106 IU VRP-neu (filled curve) or 106 IU VRP-HA (open curve). The pri-
mary serum was diluted with PBS (1:100), and FITC-labeled goat anti-mouse IgG diluted in PBS (1:1000) was used as the secondary antibody.
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lowing retraction of the skin did not reveal any tumors.
These results demonstrate that vaccination with VRP-neu
prevented spontaneous formation of tumor in the breasts of
neu transgenic mice and that tolerance to the neu trans-
gene was broken by vaccination with VRP-neu.
Induction of antigen-specific IgG by vaccination of 
MMTV-c-neu transgenic mice with VRP-neu
Immune serum was drawn from mice described at 133
days or 55 days after the third vaccination with VRP-neu or
VRP-HA (Fig. 4). Flow cytometric analysis of the immune
sera using A2L2 cells demonstrated that vaccination with
VRP-neu induced a strong IgG response that was evident
at dilutions of 1:25 (Fig. 5a) and 1:100 (Fig. 5b). Vaccina-
tion with the control VRP-HA failed to induce a neu-specific
antibody response (Fig. 5a,5b). These findings indicate that
vaccination with VRP-neu induced humoral immunity to the
protein product of the neu-transgene in neu-transgenic
mice, thus breaking any existing tolerance to p185.
Tetramer analysis of CD8+ T cells following vaccination 
with VRP-neu or VRP-HA
Ikuta and colleagues [43] identified a K(d)-restricted pep-
tide for mouse HER2/neu. The identical sequence (PYVS-
RLLGI) is present in rat HER2/neu. We therefore ordered
a tetramer containing this sequence from the National Insti-
tutes of Health Tetramer Facility at Emory University. A K(d)
tetramer specific for A/PR/8/34 influenza HA was used as
a positive control for VRP-HA-vaccinated mice. Balb/c
mice were vaccinated three times at 2-week intervals with
VRP-neu or VRP-HA, and the spleens from two mice were
collected 3 weeks after the third injection. We found that
2.38% of the pooled spleen cells from the mice that had
been vaccinated three times with VRP-neu were stained by
both the anti-CD8 antibody and the HER2/neu tetramer
(Table 1). This value is in excellent agreement with the per-
centage of dual-positive cells from mice that had been vac-
cinated with VRP-HA and stained with the HA tetramer
(2.79%). In contrast, the percentage of dual-positive cells
from the mice that had been vaccinated with VRP-HA and
stained with the HER2/neu tetramer was only 0.22%, and
the percentage from the mice that had been vaccinated
with VRP-neu and stained with the HA tetramer was only
0.37%. These results clearly demonstrate that vaccination
with VRP-neu produced antigen-specific CD8+ T cells.
Intracellular IFN-γ analysis of CD8+ T cells following 
vaccination with VRP-neu or VRP-HA
An alternative assay to tetramer analysis is measurement of
the percentage of CD8+ T cells that also contain intracellu-
lar IFN-γ after in vitro stimulation with an antigenic peptide.
We therefore vaccinated Balb/c mice three times at 2-
week intervals with VRP-neu or VRP-HA, and then removed
the spleens 3 weeks after the third injection. The in vitro
culture procedure was similar to that used for tetramer anal-
ysis except that the peptide PYVSRLLGI was cultured
directly with the immune spleen cells rather than with naïve
spleen cells. We found that 2.80% of the spleen cells from
the mice that had been vaccinated three times with VRP-
neu  stained positive for intracellular IFN-γ (Fig. 6a and
Table 2) compared with only 0.27% for spleen cells from
mice vaccinated with VRP-HA (Fig. 6b and Table 2). This
percentage (2.80%) is in excellent agreement with that of
tetramer-positive cells after vaccination with VRP-neu
(2.38%) (Table 1).
Analysis of immune spleen cells by IFN-γ ELISPOT after 
vaccination with VRP-neu or VRP-HA
We vaccinated Balb/c mice three times at 2-week intervals
with VRP-neu  or VRP-HA and removed the spleens 3
weeks after the third injection. The number of spleen cells
secreting IFN-γ in response to overnight co-culture with
Figure 2
Protection from tumor challenge after vaccination with virus-like repli- con particles (VRP)-neu Protection from tumor challenge after vaccination with virus-like repli-
con particles (VRP)-neu. Groups of seven or eight mice were vacci-
nated three times at 2-week intervals with VRP-neu or VRP-
hemagglutinin (HA). Two weeks after the final vaccination, the mice 
were challenged with A2L2 cells injected into a mammary fat pad. Five 
weeks after the tumor challenge, (a) the largest dimension of each 
tumor was measured and (b) the mice were killed and the mass of the 
tumor in each animal was determined.
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A2L2 cells in an ELISPOT assay were then determined. At
all three effector-to-stimulator ratios, vaccination with VRP-
neu  resulted in a statistically significant increase in the
number of spots per 106 spleen cells (Table 3). This finding
demonstrates that secretion of IFN-γ in response to co-cul-
ture with A2L2 cells was dependent on vaccination with
VRP-neu and did not result from vaccination with the con-
trol VRP-HA.
Discussion
Although more than a decade has elapsed since the origi-
nal descriptions of gene vaccines [46,47], a clinically
approved gene vaccine for either an infectious disease or
for cancer has yet to be developed. Gene vaccines contain-
ing elements of the Alphaviruses VEE, Sindbis virus and
Semliki Forest virus offer substantial clinical potential and
safety [22,27]. Vaccine vectors incorporating genetic
elements of Alphaviruses can be divided into two major cat-
egories [48]: expression plasmids containing viral genes
that are essential for replication and transcription of the
positive-strand RNA genome of the viruses [18,24], and
infectious but replication-incompetent viral particles in
which the genes for the viral structural proteins have been
Figure 3
Minimal effective vaccine dose in two tumor prevention models Minimal effective vaccine dose in two tumor prevention models. Groups of four or five mice were vaccinated once, twice or three times (1X, 2X, or 
3X) at 2-week intervals with virus-like replicon particles (VRP)-neu or VRP-hemagglutinin (HA) (104 IU or 105 IU). Two weeks after the final vaccina-
tion, the mice were challenged with A2L2 cells injected into a mammary fat pad or intravensouly. The mice were killed 5 weeks after the tumor chal-
lenge. (a) The mass of the mammary tumors, if present, was determined in the mammary fat pad prevention model group, and (b) the number of 
surface metastases on the lungs was determined in the experimental lung metastasis prevention model group.
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Figure 4
Inhibition of spontaneous tumor formation by vaccination with virus-like  replicon particles (VRP)-neu Inhibition of spontaneous tumor formation by vaccination with virus-like 
replicon particles (VRP)-neu. Groups of MMTV-c-neu transgenic mice 
(n = 10 per group) were vaccinated three times (▼ ) at 2-week intervals 
with 106 IU VRP-neu (▲ ) or 106 IU VRP-hemagglutinin (HA) (■ ). The 
mice vaccinated with VRP-HA were killed when moribund, and the mice 
vaccinated with VRP-neu were killed at 240 days.
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replaced by the gene for a protein antigen [20-22]. We
have previously described a gene vaccine for HER2/neu of
the first category [17]. In the present article, we describe
results of a gene vaccine for HER2/neu  of the second
category.
We report here that VRP vaccine vectors derived from an
attenuated strain of VEE containing the gene for rat HER2/
neu were highly immunogenic when used to vaccinate both
conventional mice and mice transgenic for the rat neu
gene. Immune serum from mice vaccinated once with VRP-
neu was reactive with A2L2 cells, demonstrating induction
of an antigen-specific IgG response, whereas serum from
mice that had been vaccinated with VRP-HA was nonreac-
tive (Fig. 1).
To determine whether vaccination with VRP-neu could pro-
tect mice from challenge with a breast cancer cell line engi-
neered to overexpress HER2/neu, mice that had been
vaccinated three times with either VRP-neu  or VRP-HA
were injected in a mammary fat pad with A2L2 cells. Vacci-
nation with either 105 IU or 106 IU VRP-neu protected all
but one mouse in each group from developing tumors (Fig.
2). Because our previous experiment demonstrated that a
single vaccination with 106 IU VRP-neu induced an IgG
response, we next vaccinated mice once, twice or three
times with 104 IU or 105 IU VRP-neu or the control VRP-
HA. Vaccination three times with 104 IU VRP-neu  (P =
0.0265) or twice with 105 IU VRP-neu (P = 0.0079) was
sufficient to prevent tumor growth of A2L2 cells injected
into a mammary fat pad (Fig. 3a). Mice similarly vaccinated
were also challenged with A2L2 cells injected
intravenously in the tail vein. Vaccination three times with
104 IU VRP-neu (P = 0.0317) or twice with 105 IU VRP-neu
(P = 0.0159) prevented tumor growth in the lungs (Fig. 3b).
Some mice in the vaccine groups had no visible lung
metastases 5 weeks after the tumor challenge. This finding
clearly demonstrates that vaccination with VRP-neu pre-
vented tumor growth in two tumor prevention models.
There is an important point to be considered regarding our
experimental models. We are vaccinating mice with the gene
for rat neu and we are challenging mice with a cell line also
overexpressing the gene for rat neu. We must therefore con-
sider the possibility that mice recognized rat p185 (the pro-
tein product of the HER2/neu gene) as a xenoantigen and
that vaccination with VRP-neu merely boosted, but did not
initiate, an immune response. We addressed this question
by vaccinating rat neu transgenic mice, which are immuno-
logically tolerant to rat p185. MMTV-c-neu transgenic mice
express the rat neu  transgene under the control of the
murine mammary tumor virus promoter and spontaneously
develop neu+ breast cancer. Vaccination of these transgenic
mice with VRP-neu very clearly demonstrated (P < 0.0001)
that the mice survived to 240 days old (Fig. 4), at which time
the experiment was concluded. On postmortem examination,
no tumor was detected in the breast of any mouse that had
been vaccinated with VRP-neu. All mice in the control group
that had been vaccinated with VRP-HA were moribund
owing to extensive breast cancer by 200 days. This result is
much more dramatic than our previous finding that vaccina-
tion of MMTV-c-neu transgenic mice with the Sindbis/DNA
plasmid-based ELVIS replicon vector increased survival of
the transgenic mice but failed to protect against tumor for-
mation and death [17]. To determine whether vaccination of
the MMTV-c-neu transgenic mice with VRP-neu induced an
IgG response, as we found in Balb/c mice (Fig. 1), we tested
Figure 5
Flow cytometric analysis of A2L2 cells with sera from MMTV-c-neu  mice vaccinated with virus-like replicon particles (VRP)-neu or VRP- hemagglutinin (HA) Flow cytometric analysis of A2L2 cells with sera from MMTV-c-neu 
mice vaccinated with virus-like replicon particles (VRP)-neu or VRP-
hemagglutinin (HA). Immune serum from the mice (described in Fig. 4) 
was drawn at 133 days. The serum was analyzed at dilutions of (a) 
1:25 and (b) 1:100. Filled curve, sera from VRP-neu-vaccinated mice; 
open curve, sera from VRP-HA-vaccinated mice. The secondary anti-
body, FITC-labeled goat anti-mouse IgG, was diluted in PBS (1:1000).
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the serum of the vaccinated neu-transgenic mice at 133
days old. Vaccination with VRP-neu induced a strong, anti-
gen-specific IgG response in these transgenic mice (Fig. 5).
Vaccination with VRP-neu therefore overcame tolerance to
p185 (Fig. 5).
In our present study, we performed three separate in vitro T-
cell assays to determine whether vaccination with VRP-neu
induces antigen-specific T cells. In the first assay we used
tetramers containing an antigenic peptide of HER2/neu to
analyze spleen cells from mice vaccinated with VRP-neu. As
a positive control we used a tetramer containing an antigenic
peptide of HA. We found that 2.38% of the CD8+ spleen
cells resulting from vaccination with VRP-neu were positive
for tetramer binding (Table 1), a value in excellent agreement
with the 2.79% of the spleen cells from VRP-HA-vaccinated
mice that were positive for an HA-specific tetramer. We fur-
ther analyzed the induction of antigen-specific CD8+ T cells
resulting from VRP-neu vaccination by performing intracellu-
lar IFN-γ analysis. We found that 2.80% of CD8+ cells from
VRP-neu-vaccinated mice were positive for intracellular IFN-
γ (Table 2), a value in excellent agreement with the 2.38%
tetramer-binding cells (Table 1). In the third assay we meas-
ured the number of IFN-γ secreting cells by ELISPOT analy-
sis (Table 3). At all three effector:stimulator ratios, the
number of IFN-γ secreting cells in the VRP-neu-vaccinated
spleen cells was significantly greater than that in the VRP-
HA-vaccinated spleen cells.
These three independent assays clearly demonstrate that
vaccination with VRP-neu induced antigen-specific CD8+ T
lymphocytes. The tetramer and intracellular IFN-γ assays
further indicate that immune spleen cells were able to rec-
Table 1
Tetramer analysis of CD8+ T cells after vaccination three times with virus-like replicon particles (VRP)-neu or VRP-hemagglutinin 
(HA)
Vaccination CD8+ cells (%) Tetramer-positive CD8+ cells (%) Tetramer-positive CD8+/CD8+ (%)
neu-specific tetramer
VRP-neu 15.98 0.38 2.38
VRP-HA 23.06 0.05 0.22
HA-specific tetramer
VRP-neu 16.01 0.06 0.37
VRP-HA 17.46 0.50 2.79
Table 2
Intracellular interferon-γ analysis of CD8+ T cells after 
vaccination three times with virus-like replicon particles (VRP)-
neu or VRP-hemagglutinin (HA)
Vaccination Isotype control (%) Interferon-γ+/CD8+ (%)
VRP-neu 0.10 2.80
VRP-HA 0.14 0.27
Naïve 0.03 0.39
Figure 6
Intracellular interferon (IFN)-γ analysis of spleen cells from vaccinated  mice Intracellular interferon (IFN)-γ analysis of spleen cells from vaccinated 
mice. Spleen cells from mice vaccinated three times with (a) virus-like 
replicon particles (VRP)-neu or (b) VRP-hemagglutinin (HA) were ana-
lyzed for the presence of intracellular IFN-γ after in vitro culture with a 
neu-specific peptide.
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Table 3
Interferon-γ ELISPOT assay after vaccination with virus-like 
replicon particles (VRP)-neu or VRP-hemagglutinin (HA)
Effector:stimulator VRP-neu 
(spots/106 cells)
VRP-HA 
(spots/106 cells)
100:1 99a 11
50:1 126a 17
25:1 129a 25
Effector only 2 5
Concanavalin A 256a,b Not determined
aP = 0.05 by Student's t test.
bSpleen cells stimulated with concanavalin A as a positive control for 
the assay.Breast Cancer Research    Vol 7 No 1    Wang et al.
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ognize an antigenic peptide of p185 presented on the
A2L2 cells used for the ELISPOT assay.
The in vivo and in vitro experiments described demonstrate
that vaccination induced antigen-specific cell-mediated
and humoral immunity, but they do not indicate the role that
each type of immunity may have played in the resulting anti-
tumor effect. Therefore, although vaccination with VRP-neu
produced antigen-specific IgG in both conventional and
transgenic mice, whether this antibody played a role in the
antitumor effect remains unclear. Pilon and colleagues [49]
reported that antibody was not required for the antitumor
effect of a plasmid vaccine against HER2/neu. Lindenc-
rona and colleagues [50] similarly induced antitumor immu-
nity against HER2/neu in B cell-deficient mice. Although T-
cell immunity alone may be sufficient in tumor prevention
models in mice, a clinical trial showed that trastuzumab
clearly benefited patients and increased the antitumor
effect of a whole-cell vaccine to HER2/neu [51].
Conclusion
Our findings demonstrate that vaccination with VRP-neu
inhibited or eliminated tumor growth in prevention models
in which breast tumor cells had been injected either in the
mammary fat pad or intravenously. Vaccination with VRP-
neu  also prevented tumorigenesis in transgenic mice in
which the neu gene was expressed in the breasts under the
control of an MMTV promoter. Vaccination with VRP-neu
induced antigen-specific CD8+, and this finding corre-
sponded with the absence or inhibition of tumor growth.
Furthermore, vaccination with VRP-neu induced antigen-
specific IgG in both conventional and transgenic mice, and
tolerance to HER2/neu in neu-transgenic mice was broken
by vaccination with VRP-neu. These findings suggest that
VRP-neu constitutes a powerful gene vaccine that induces
both cellular and humoral immunity against HER2/neu. We
speculate that such vaccination could be more effective
than passive immunotherapy using monoclonal antibodies
such as trastuzumab in patients with breast cancer.
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